Ewen Crouch AM
CHAIRMANEwen Crouch joined the board on 21 April 2022 and has been declared as the Chairman on 30 April 2022.
Ewen is currently Chairman of Corporate Travel Management Limited (ASX: CTD) and serves on the Boards of BlueScope Steel Limited (ASX: BSL) and non-profit organisation called Jawun.
From 1988-2013 Ewen was a partner at Allens, wherein he served as Chairman of Partners for 4 years. During his time at Allens, Ewen had several practice leadership and management roles, including 11 years’ service on the firm’s board.
Between February 2013 & December 2019, he served as a Director of Westpac Banking Corporation. He was previously a director of Mission Australia including seven years as Chairman, a member of the Takeovers Panel, a member of the Commonwealth Remuneration Tribunal and a director of Sydney Symphony Orchestra.
Ewen is a Fellow of the Australian Institute of Company Directors.
GEOFF CUMMING, B.APP.SC, B.SC.(HONS.), MBA, PHD, MAICD
NON-EXECUTIVE DIRECTOR– Nomination and Remuneration Committee Member
– Audit and Risk Committee Member
– Managing Director and CEO (Jan 2009 – Jun 2016)
– Non-Executive Director (Jun 2016 – )
Dr Cumming has over 20 years experience in the healthcare and biotechnology market. Geoff’s roles have progressed from pure research to sales and marketing roles through to Managing Director level and Board seats. Previously Managing Director of Roche Diagnostic Systems – Oceania Regional Centre, where he transformed a loss-making business to one achieving over 30% compound annual growth over a four year period and the highest profitability levels in Roche’s global organisation. Geoff was also Managing Director and CEO of Biosceptre International Ltd, a Cambridge (UK) based biotechnology company commercialising a range of products in cancer treatment and diagnosis. Dr Cumming is the Non-Executive Chairman of Bard1 Life Sciences Limited (ASX:BD1).
CHRISTOPHER PARKER
NON EXECUTIVE DIRECTORChristopher Parker’s career in the medical diagnostic and device industry spans more than 30 years. Having worked all over the world, he has developed substantial global experience of diverse healthcare environments and has a keen interest in emerging technologies. Beginning his career as a Medical Laboratory Scientist in Australia, Christopher then moved to the commercial sector in a business management role and spent almost 14 years working in the Australian in-vitro diagnostics industry. Christopher joined Roche Diagnostics in 1997 and over the next twenty years held roles of increasing scope and responsibility in sales, marketing, business development and country management across the Asia Pacific region (Singapore, Taiwan and India), in Canada and the United Kingdom. In 2017, Christopher retired from Roche Diagnostics, moved back to Australia and has since formed Stratigent Consulting, an organisation that specialises in providing customised, professional advice in the areas of Business Development, Change Management and People Leadership.
Ms. Glenda McLoughlin
NON EXECUTIVE DIRECTORMs. Glenda McLoughlin is an experienced Non-Executive Director with over 25 years’ experience as an Investment Banker and Senior Executive working in Australia, Asia, the UK and the US. She has held senior executive roles at leading financial institutions Morgan Stanley, Credit Suisse and Barclays Capital where she led the Energy and Infrastructure Group in Australia. In addition to her work in the energy sector, Glenda has experience in the medical diagnostics, telecommunications, information technology, media, transport and financial services sectors. Glenda co-founded listed Australian gas company Metgasco Ltd, where she was Executive Director and Chief Financial Officer for eight years. Glenda holds a Bachelor of Economics and Master of Business Administration and is a Fellow of the Australian Institute of Company Directors.
Ms. McLoughlin currently holds the positions of Non-Executive Director with Senex Energy Ltd where she chairs the Audit and Risk Committee and is Chair of SCEGGS Redlands.
Ms. McLoughlin is Chair of AnteoTech’s Audit and Risk Committee.
Dr Katherine Woodthorpe AO
NON EXECUTIVE DIRECTORDr Katherine Woodthorpe AO is an experienced Chair and Non-Executive Director serving for 20 years on the boards of a variety of organisations including listed entities, government boards and for-purpose organisations. She has a strong track record in a broad range of innovation-dependent industries including healthcare, renewable energy and environmental and climate science. She has been cited in various media as one of Australia’s most influential people in innovation. Katherine has deep knowledge of the private equity and venture capital industries in the financial sector as well as working closely with superannuation funds on their alternative investments in the private equity space. For seven years she was the Chief Executive of AVCAL, the Australian Private Equity and Venture Capital Association. Prior to AVCAL, she held a broad range of management and board positions, in Australia and overseas. Katherine commenced her career initially as a chemist then moved to sales of specialised laboratory equipment into the medical and oil, gas and petrochemical sectors covering the geographies of Europe, Asia and the Middle East before locating permanently to Australia in 1988. Katherine holds a Bachelor of Science (Manchester Uni.) and Ph.D. (Chemistry, Leicester Uni, UK).
Dr. Woodthorpe, amongst several positions, is a Non-Executive Director of the Olivia Newton John Cancer Research Institute, Bioplatforms Australia Ltd and Vast Solar Pty Ltd.